title: [Clinical utilization of new anti-epileptic agents].
abstract: Since the beginning of the 1990's, a dozen of new anti-epileptic drugs have been on the market or will be soon. This article reviews the daily clinical utilisation of new anti-epileptic drugs. It considers, without being complete, the current opinions and tendencies. The new anti-epileptic substances are generally as efficient as conventional medications. However, they are better tolerated and are more easily used in combination with conventional anti-epileptic drugs. Polytherapy is certainly the form of treatment, which is used in the most cases of resistant epilepsies. The surgical treatment can be used in only a very limited number of cases. The objective of treatment is the complete control of seizures, with minimum secondary effects. Though this objective is rarely reached, the NAE significantly improves the quality of life of patients suffering from severe epilepsy. The utilisation of NAE is not without risk. Increase in the frequency and severity of seizures may occur; we should remember that severe adverse effects appeared in the post-marketing period of the use of Vigabatrine and Felbamate. Therefore, we must remain vigilant in the clinical use of the anti-epileptic drugs.
authors.affiliation: Fondation Institution de Lavigny.
authors.forename: G B
authors.initials: GB
authors.lastname: Foletti
mesh_terms: D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D000741:Anemia, Aplastic / Q000139:chemically induced; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D004827:Epilepsy / Q000188:drug therapy*; D000078328:Felbamate; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D000077213:Lamotrigine; D000077287:Levetiracetam; D009557:Nipecotic Acids / Q000627:therapeutic use; D000078330:Oxcarbazepine; D048448:Phenylcarbamates; D010889:Piracetam / Q000031:analogs & derivatives / Q000627:therapeutic use; D011409:Propylene Glycols / Q000009:adverse effects; D000078308:Tiagabine; D000077236:Topiramate; D014227:Triazines / Q000627:therapeutic use; D020888:Vigabatrin / Q000009:adverse effects; D014794:Visual Fields / Q000187:drug effects; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D009557:Nipecotic Acids; D048448:Phenylcarbamates; D011409:Propylene Glycols; D014227:Triazines; D000077236:Topiramate; D005632:Fructose; D002220:Carbamazepine; D000077287:Levetiracetam; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D020888:Vigabatrin; D000077213:Lamotrigine; D000078330:Oxcarbazepine; D000078328:Felbamate; D000078308:Tiagabine; D010889:Piracetam